TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02569996
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab will be administered at 375 mg/m\^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
Study: NCT01766024
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
Study: NCT02312934
Drug: Transdermal nicotine
Normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.
Study: NCT00199381
Drug: Istradefylline
Normalized name: istradefylline
DrugBank: Istradefylline (DB11757)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral istradefylline (KW-6002) 20 or 40 mg once daily.
Study: NCT01940952
Drug: Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg
Normalized name: donepezil hydrochloride 5 MG
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01940952
Drug: Placebo + Donepezil 5mg or 10mg
Normalized name: donepezil hydrochloride 10 MG
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01940952
Drug: Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg
Normalized name: donepezil hydrochloride 5 MG
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01586364
Drug: Ospemifene 60Mg Oral Tablet
Normalized name: ospemifene 60 MG
DrugBank: Ospemifene (DB04938)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02173158
Drug: lomitapide
Normalized name: Lomitapide
DrugBank: Lomitapide (DB08827)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03740724
Drug: veledimex
Normalized name: Veledimex
DrugBank: Veledimex (DB12170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veledimex, is a small molecule which activates the RTS to induce expression of MMP-1 and is and provided as a liquid filled gelatin capsule for oral administration
Study: NCT01295814
Drug: Adalimumab
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
Study: NCT00988910
Drug: EE30-DRSP (Yasmin, BAY86-5131)
Normalized name: DRSP
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: DRSP-containing combined oral contraceptives according to the normal routine praxis
Study: NCT00988910
Drug: Other combined oral contraceptives
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other combined oral contraceptives according to the normal routine praxis
Study: NCT01157819
Drug: 0.3% Ciprofloxacin Ear Drops
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 gtt b.i.d. for 7 days.
Study: NCT01817218
Drug: Platelet Rich Plasma
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02661789
Drug: Goserelin 3.6 mg implant
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pharmacologically induced biphasic sex-steroid hormone fluctuation
Study: NCT00411229
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV infusion, 130mg/m²
Study: NCT01687985
Drug: BLI801 laxative - low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BLI801 laxative - oral solution
Study: NCT01687985
Drug: BLI801 laxative - high dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLI801 laxative - oral solution
Study: NCT02911285
Drug: N-acetylcysteine
Normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1200mg bid (2400mg/day)
Study: NCT01397409
Drug: ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab 0.5 mg given by intravitreal injection.
Study: NCT02511691
Drug: 18F-PSS232
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic PET Tracer
Study: NCT04427306
Drug: T-Vec
Normalized name: T-Vec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: (talimogene laherparepvec) will be given prior to surgery. Standard care the patients receive the drug after sugery
Study: NCT02218424
Drug: Magnesium
Normalized name: Magnesium
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04275024
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The topical treatment in the study was calcipotriol ointment(Dovonex;LEO Laboratories Ltd, Ireland) twice daily for 12 weeks.
Study: NCT04275024
Drug: PSORI-CM01 Granule
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PSORI-CM01#YXBCM01# granule 5.5g os once a day for 12weeks.
Study: NCT01013805
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).~Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.
Study: NCT02427412
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
Study: NCT02427412
Drug: Saline water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 ml of Saline water injected into the knee capsula at the end of surgery.
Study: NCT02427412
Drug: Tranexamic Acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
Study: NCT00702637
Drug: Modafinil
Normalized name: Modafinil
DrugBank: Modafinil (DB00745)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01265511
Drug: SCY-635
Normalized name: SCY-635
DrugBank: SCY-635 (DB12451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCY-635 tablets, 300 mg bid for 28 days
Study: NCT01265511
Drug: Pegasys
Normalized name: Pegasys
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 180 ug prefilled syringe given once per week for up to 48 weeks
Study: NCT01265511
Drug: Copegus
Normalized name: Copegus
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tablets given bid for up to 48 weeks
Study: NCT02993731
Drug: Napabucasin
Normalized name: Napabucasin
DrugBank: Napabucasin (DB12155)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.
Study: NCT02993731
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
Study: NCT02993731
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nab-paclitaxel 125 mg/m\^2 immediately followed by gemcitabine 1000 mg/m\^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
Study: NCT03651011
Drug: Aflibercept Injection [Eylea]
Normalized name: aflibercept Injection [Eylea]
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection 2 mg Eylea every 4 weeks M0-M2 (loading phase). M3-M12: continue in a pro re nata treatment regimen.
Study: NCT02760420
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
Study: NCT00758667
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed
Study: NCT00574197
Drug: Mycophenolate Sodium
Normalized name: Mycophenolate Sodium
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1440mg/day (720mg by mouth, twice a day)
Study: NCT00211133
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03574584
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive semaglutide s.c. injection(s) once-weekly for 20 weeks. The dose will be escalated over 16 weeks to a final dose level that will be maintained for 4 weeks.
Study: NCT02873806
Drug: Topical travoprost
Normalized name: Travoprost
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: - Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.
Study: NCT02873806
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):~* Week 1: 1 drop four (4) times per day in the study eye~* Week 2: 1 drop three (3) times per day in the study eye~* Week 3: 1 drop two (2) times per day in the study eye~* Week 4: 1 drop one (1) time per day in the study eye
Study: NCT00646737
Drug: Mycophenolate sodium
Normalized name: Mycophenolate Sodium
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mycophenolate sodium
Study: NCT00711009
Drug: lopinavir/ritonavir (LPV/r)
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: LPV/r 400/100 mg BID
Study: NCT00711009
Drug: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FTC/TDF 200/300 mg QD
Study: NCT00711009
Drug: raltegravir (RAL)
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RAL 400 mg BID
Study: NCT03359811
Drug: Bupivacaine HCl
Normalized name: bupivacaine HCl
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg of Bupivacaine HCl in 10 cc of preservative free normal saline (PFNS) injected before surgical incision in each of the four quadrants.
Study: NCT03359811
Drug: Liposomal Bupivacaine
Normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 65 mg of Liposomal Bupivacaine in 10 cc of PFNS injected before surgical incision in each of the four quadrants.
Study: NCT03898882
Drug: oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PK measurements of oxytocin
Study: NCT01539473
Drug: TR-701 FA with Tyramine
Normalized name: tyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR-701 FA 200 mg oral and Tyramine
Study: NCT01539473
Drug: Placebo-controlled withTyramine
DrugBank: Tyramine (DB08841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-controlled and Tyramine
Study: NCT01189201
Drug: BI 10773/linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: medium single dose of BI 10773/linagliptin FDC (Formulation A1)
Study: NCT01189201
Drug: BI 10773/linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: medium single dose of BI 10773/linagliptin FDC (Formulation A3)
Study: NCT01189201
Drug: BI 10773/linagliptin SID
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: medium single dose of mono components BI 10773/linagliptin
Study: NCT01189201
Drug: BI 10773/linagliptin FDC
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
Study: NCT04260360
Drug: NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NanoDoce is manufactured using a Precipitation with Compressed Antisolvent (PCA) technique that employs supercritical carbon dioxide and acetone to generate docetaxel nanoparticles within a well-characterized particle-size distribution. Prior to administration, the NanoDoce powder in vial is suspended with a sterile solution of Polysorbate 80 (0.0075% - 0.0375% (w/w))/Ethanol (0.06% - 0.3% (w/w)) in 0.9% Sodium Chloride for injection.
Study: NCT01277757
Drug: Akt Inhibitor MK2206
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally (PO) weekly, starting (dose 0) at 200 mg
Study: NCT03980054
Drug: Pyrotinib
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrotinib 400 mg, orally once daily for one year
Study: NCT03959891
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib is a type of inhibitor that is believed to work by inhibiting Akt.
Study: NCT03959891
Drug: Fulvestrant
Normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hormone therapies work by stopping the production of a certain hormone, blocking hormone receptors, or substituting chemically similar agents for the active hormone, which cannot be used by the tumor cell.
Study: NCT03959891
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib (Ibrance®) is a drug that can be used along with an aromatase inhibitor to treat women with advanced hormone receptor-positive breast cancer. Palbociclib is a reversible small molecule cyclin-dependent kinase (CDK) inhibitor. The drug blocks proteins in the cell called cyclin-dependent kinase (CDK) 4 and CDK 6. In hormone positive breast cancer cells, blocking these proteins helps stop the cells from dividing to make new cells. It helps prevent the cells from moving from G1 to S cell cycle phase in the division process. This slows cancer growth.
Study: NCT02083354
Drug: Dabrafenib
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt)
Study: NCT02083354
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
Study: NCT00578331
Drug: Olopatadine 0.6% nasal spray
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 sprays each nostril twice daily
Study: NCT03852901
Drug: empagliflozin (Jardiance) 25 mg
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral empagliflozin 25 mg/day x 14 days
Study: NCT00275704
Drug: Flaxseed
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03312634
Drug: Palovarotene
Normalized name: palovarotene
DrugBank: Palovarotene (DB05467)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palovarotene was taken orally once daily at approximately the same time each day following a meal.
Study: NCT04859738
Drug: Lidocaine Spray
Normalized name: lidocaine Mucosal Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individuals who met the research criteria and signed the informed consent form were numbered according to the order in which they came to the hospital. Later, the numbered individuals were assigned to the study groups according to the randomization list created in the computer environment.~Lidocaine Spray was applied 60 seconds before to the area where the peripheral intravenous catheter application of the patients in the Experiment I Group (Lidocaine Spray) will be performed. After waiting 60 seconds, peripheral intravenous catheter application was performed.~The nurse responsible for data collection measured blood pressure, pulse rate and peripheral oxygen saturation values 5 minutes before and just after the application with a finger-type pulse oximeter.~After performing peripheral intravenous catheterization, the pain level felt by the individual during the procedure and the injection satisfaction level values were taken and recorded on the Case Report Form by the nurse.
Study: NCT00671294
Drug: Ramelteon and Placebo (9 possible combinations total)
Normalized name: Ramelteon
DrugBank: Ramelteon (DB00980)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Randomized sequence over two consecutive nights for a total of three treatment periods to include the following:~Ramelteon 4 mg, tablets, orally over two nights~Ramelteon 8 mg, tablets, orally over two nights~Ramelteon placebo-matching tablets, orally over two nights
Study: NCT01615120
Drug: GTx-758 125 mg
Normalized name: toremifene
DrugBank: GTX-758 (DB14969)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One 125 mg tablet once a day
Study: NCT00182572
Drug: buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00182572
Drug: naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01615120
Drug: GTx-758 250 mg
Normalized name: toremifene
DrugBank: GTX-758 (DB14969)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: two 125 mg tablets once daily
Study: NCT01319539
Drug: Akt Inhibitor MK2206
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00852800
Drug: Albumin
Normalized name: Albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
Study: NCT00852800
Drug: Albumin
Normalized name: Albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
Study: NCT00000385
Drug: Lithium
Normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium 600 mg to 2700 mg per day
Study: NCT03922945
Drug: VI-0521 oral capsule
Normalized name: VIS-410
DrugBank: VIS-410 (DB19067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine/Topiramate
Study: NCT02124369
Drug: Abraxane
Normalized name: Abraxane
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 125mg/m2, IV, on days 1,8 \& 15 of each 28 day cycle, up to 6 cycles.
Study: NCT02124369
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000mg/m2, IV, on days 1,8 \& 15 of a 28 day cycle, up to 6 cycles.
Study: NCT02130817
Drug: Belatacept
Normalized name: Belatacept
DrugBank: Belatacept (DB06681)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Belatacept will be added to the standard of care regimen and will be given at days 0,5, weeks 2, 4, 8 and 12 (10 mg/kg) and every 4 weeks (5 mg/kg) for one year.
Study: NCT02130817
Drug: Tacrolimus withdrawal
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus dosing will begin on Days 1 through 5 post transplant at up to 2 mg BID to achieve target trough levels of 9-11 ng/ml. The dose will be tapered through the end of week 2 to achieve a trough level of 4 ng/ml which will be maintained for six weeks. Tacrolimus will be withdrawn at the end of eight weeks post transplant.
Study: NCT03935074
Drug: intra-arterial administration of melphalan
Normalized name: melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01493440
Drug: atosiban
Normalized name: atosiban
DrugBank: Atosiban (DB09059)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
Study: NCT02130817
Drug: Thymoglobulin (ATG)
Normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin (ATG) Induction. Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg via a peripheral or central vein, starting in the operating room.
Study: NCT02130817
Drug: Myfortic
Normalized name: Myfortic
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
Study: NCT01029275
Drug: Pre-treatment with octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-treatment with octreotide
Study: NCT01702311
Drug: Bedtime insulin Aspart (Novolog)
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bedtime insulin aspart supplementation based on blood glucose value in the bedtime supplementation arm.
Study: NCT00830882
Drug: levosalbutamol
Normalized name: Levosalbutamol
DrugBank: Levosalbutamol (DB13139)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 puffs four times a day for 2 weeks
Study: NCT01178047
Drug: Rasagiline
Normalized name: Rasagiline
DrugBank: Rasagiline (DB01367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
Study: NCT03613974
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive different lidocaine concentrations
Study: NCT00784225
Drug: selenium
Normalized name: Selenium
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mcg daily for 7-12 years
Study: NCT00784225
Drug: vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 IU daily by mouth for 7-12 years